Last reviewed · How we verify

fluticasone/salmeterol, tiotropium — Competitive Intelligence Brief

fluticasone/salmeterol, tiotropium (fluticasone/salmeterol, tiotropium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inhaler: corticosteroid + long-acting beta-2 agonist + long-acting muscarinic antagonist. Area: Respiratory / Pulmonology.

marketed Combination inhaler: corticosteroid + long-acting beta-2 agonist + long-acting muscarinic antagonist Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol); M3 muscarinic receptor (tiotropium) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

fluticasone/salmeterol, tiotropium (fluticasone/salmeterol, tiotropium) — Taipei Veterans General Hospital, Taiwan. This combination inhaler delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (salmeterol) to dilate airways, plus a long-acting muscarinic antagonist (tiotropium) for sustained bronchodilation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
fluticasone/salmeterol, tiotropium TARGET fluticasone/salmeterol, tiotropium Taipei Veterans General Hospital, Taiwan marketed Combination inhaler: corticosteroid + long-acting beta-2 agonist + long-acting muscarinic antagonist Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (salmeterol); M3 muscarinic receptor (tiotropium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inhaler: corticosteroid + long-acting beta-2 agonist + long-acting muscarinic antagonist class)

  1. Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fluticasone/salmeterol, tiotropium — Competitive Intelligence Brief. https://druglandscape.com/ci/fluticasone-salmeterol-tiotropium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: